

2017-07-10

Cellular prion protein (PrPC) in the development of Merlin-deficient tumours

Provenzano, L

<http://hdl.handle.net/10026.1/9710>

10.1038/onc.2017.200

Oncogene

Springer Science and Business Media LLC

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

Cellular prion protein (PrP^C) in the development of Merlin-deficient tumours

Provenzano Lucy¹, Ryan Yan¹, Hilton David ², Lyons Rimmer Jade¹, Dave Foram¹, Maze Emmanuel Atangana¹, Adams Claire¹, Rigby-Jones Rosemarie ²; Ammoun Sylwia^{1*} and Hanemann C Oliver.^{1*}

¹Institute of Translational and Stratified Medicine, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth PL6 8BU, UK

²Department of Cellular and Anatomical Pathology, Derriford Hospital, Plymouth, UK

* Both authors contributed equally to this work.

E mail: sylwia.ammoun@plymouth.ac.uk

Corresponding author:

Sylwia Ammoun (MSc, PhD), Research Fellow in Clinical Neurobiology

Plymouth University Peninsula Schools of Medicine and Dentistry

The Institute of Translational and Stratified Medicine

The John Bull Building, Tamar Science Park, Research Way, Plymouth, PL6 8BU.

Phone: +441752437424

Running title: PrP^C in Merlin-deficient tumours

This work was supported by The Laura Crane Youth Cancer Trust and Brain Tumour Research

Abstract

Loss of function mutations in the gene neurofibromatosis Type 2 (*NF2*), coding for a tumour suppressor Merlin, cause multiple tumours of the nervous system such as schwannomas, meningiomas and ependymomas. These tumours may occur spontaneously or as part of the hereditary condition Neurofibromatosis Type 2 (NF2). Current treatment is confined to (radio) surgery and no drug therapies exist. *NF2* mutations and/or Merlin inactivation are also seen in other cancers including some mesothelioma, breast cancer, colorectal carcinoma, melanoma and glioblastoma. To study the relationship between Merlin-deficiency and tumourigenesis we have developed an *in vitro* model comprising human primary schwannoma cells, the most common Merlin-deficient tumour and the hallmark for NF2. Using this model we show increased expression of cellular prion protein (PrP^C) in schwannoma cells and tissues. Additionally, a strong overexpression of PrP^C is observed in human Merlin-deficient mesothelioma cell line TRA and in human Merlin-deficient meningiomas. PrP^C contributes to increased proliferation, cell-matrix adhesion and survival in schwannoma cells acting via 37/67kDa non-integrin laminin receptor (LR/37/67kDa) and downstream ERK1/2, PI3K/AKT and FAK signalling pathways. PrP^C protein is also strongly released from schwannoma cells via exosomes and as a free peptide suggesting that it may act in an autocrine and/or paracrine manner. We suggest that PrP^C and its interactor, LR/37/67kDa, could be potential therapeutic targets for schwannomas and other Merlin-deficient tumours.

Key words

Cellular Prion Protein (PrP^C), Merlin-deficient tumours, Schwannoma, Neurofibromatosis Type 2 (NF2), 37/67kDa non-integrin laminin receptor

Introduction

Mutations in a gene coding for the tumour suppressor protein Merlin (*NF2*) lead to the development of multiple tumours of the nervous system including schwannomas, meningiomas and ependymomas. These tumours occur spontaneously or as a part of the hereditary disease Neurofibromatosis type 2 (NF2) (1). *NF2* gene mutations/Merlin inactivation are also found in proportion of breast cancer, colorectal carcinoma, melanoma, glioblastoma and mesothelioma (2). Current treatments for NF2, surgery and radiosurgery, are invasive and cannot be used in all patients, therefore new drug-based treatments are needed (3). Schwannoma is the most common Merlin-deficient tumour and the hallmark for NF2 (4). Using a primary human schwannoma *in vitro* cell model we have previously uncovered signalling pathways involved in schwannoma development including; ERK1/2, FAK, Src, NF κ B, JNK, PI3K/AKT, p53/MDM2 and the ubiquitin ligase CRL4^{DCAF1} (5-8).

A cDNA array hybridisation and RT-PCR highlighted significantly increased activity of the prion protein (PrP)-encoding gene, *PRNP*, in schwannoma compared to Schwann cells (9). Cellular prion protein PrP^C is a *N*-glycosylated protein, tethered to the cell membrane via a C-terminal glycosyl-phosphatidylinositol (GPI) anchor (10). PrP^C is expressed in CNS neurons and glial cells (10) as well as in PNS axons and associated Schwann cells (11) displaying important biological functions such as myelination maintenance, neural precursor proliferation and adult neurogenesis (12-14). PrP^C is overexpressed in different cancers including colorectal cancer, breast cancer, pancreatic cancer and melanoma regulating proliferation, cell adhesion and survival (15) via key signalling pathways [cyclin D1, ERK1/2, caspase-3 and PI3K/AKT (16, 17)], previously shown to be involved in schwannoma development (18, 19). PrP^C can be released from cells, taking part in autocrine and/or paracrine

signalling (20, 21). PrP^C has been shown to bind to the cell surface 37/67kDa laminin receptor protein (LR/37/67kDa) which could be potentially targeted by anti-LR 37/67kDa antibodies (22) and LR/37/67kDa/laminin interaction inhibitor NSC47924 (23).

We demonstrate, for the first time, that (a) PrP^C protein is strongly overexpressed in schwannoma compared to control Schwann cells/tissues; (b) that this overexpression is negatively regulated by Merlin and depends on NFκB; (c) PrP^C levels are also highly increased in Merlin-deficient human mesothelioma cell line TRA and Merlin-deficient human meningioma grade I tissues and primary cells; (d) PrP^C increases schwannoma cell proliferation, survival and cell-matrix adhesion acting via LR/37/67kDa and downstream ERK1/2, PI3K/AKT, and FAK signalling pathways; (e) PrP^C is released from schwannoma cells, both via exosomes and also as cleaved peptides. We therefore suggest that decreasing PrP^C levels either by using humanized anti-PrP antibody PRN100 [clinical trials are planned by MRC Prion Unit for sporadic Creutzfeldt-Jakob disease (24)]; or proteasome inhibitor (targeting NFκB) Bortezomib [FDA approved for multiple myeloma (25)]; or targeting PrP^C receptor and/or the, LR/37/67kDa laminin receptor, using inhibitors such as NSC47924 (23) or antibodies (22) could be a good therapeutic strategy for schwannoma and other Merlin-deficient tumours.

Results

Cellular di-glycosylated form of prion protein PrP^C is strongly overexpressed in schwannoma

Immunocytochemistry shows increased PrP staining in Merlin negative human primary schwannoma cells (NF2^{-/-}), throughout the cytoplasm and cell membranes (Figure 1a, right panel) compared to the weak staining seen in control human Schwann cells (NF2^{+/+}) (Figure 1a, left panel). Immunohistochemistry on formalin-fixed, paraffin-embedded tissues also shows a very high level of PrP expression in human schwannoma tumours (Figure 1b, third panel) compared to healthy nerve (Figure 1b, first panel) and traumatic neuroma (Reactive non-neoplastic proliferation of, Schwann cells and perineurial cells caused by injury or trauma) sections (Figure 1b, second panel). These data are confirmed by Western blotting, demonstrating a strong PrP overexpression in schwannoma compared to Schwann cells and tissues (Figure 1c and Supplementary Figure 1a right panel).

To define which form of the PrP is overexpressed in schwannoma (i.e. either the normal cellular PrP^C, or pathogenic infectious proteinase K-resistant PrP^{Res}), cells were either lysed normally with the addition of protease inhibitors or with proteinase K (16). Western blot analysis of schwannoma lysates treated with proteinase K show complete ablation of PrP (Figure 1d, right lane) compared to control (Figure 1d, left lane) suggesting that the cells express cellular PrP^C and not PrP^{Res}.

Mature, di-glycosylated PrP^C has been linked to resistance to apoptosis in several cancers whereas lack of glycosylation is linked to PrP^C to PrP^{Res} conversion (26). Using a PNGaseF de-glycosylation assay we show that the PrP^C expressed in both Schwann and schwannoma cells is di-glycosylated (Figure 1e left panel). Both samples show two clear de-glycosylated bands which account for the presence of

mono- and completely un-glycosylated PrP^C after treatment with PNGaseF. The replicates are highly variable but no difference in the ratio of mono-: un-glycosylated bands between Schwann and schwannoma samples was observed (Figure 1e right panel).

PrP^C overexpression is due to increased transcription and translation and not due to decreased proteosomal degradation

Treatment of schwannoma cells with transcription inhibitor actinomycin D (ActD) (10nM, 24h) (Figure 1f) and translation inhibitor cycloheximide (CHX) (1μM, 24h) reduced PrP^C levels by ~80% (Figure 1g). Additionally, proteosomal degradation inhibitor MG132 (1μM, 24h) increased PrP^C level by ~50% (Figure 1h). These and our previous data on *PRNP* gene activation in schwannoma (9), suggest that increased PrP^C level is due to increased transcription and translation and not due to intracellular accumulation caused by decreased proteosomal degradation (27). Similarly to schwannoma, PrP^C is also upregulated in human Merlin-deficient mesothelioma cell line TRA (28) (Figure 1i) and in Merlin-deficient human grade I meningioma tissues (Figure 1j) and primary cells (Figure 1k and Supplementary Figure 1b) compared to controls.

Merlin-reintroduction is sufficient to reduce PrP^C levels in Merlin-deficient-schwannoma and -mesothelioma but not -meningioma cells

To investigate if PrP^C overexpression is due to Merlin deficiency we reintroduced Merlin (*NF2*) wild-type protein into schwannoma, TRA and meningioma grade I cells, using recombinant adenovirus AdNF2 (29). Interestingly, Merlin-reintroduction reduced PrP^C levels in both schwannoma (Figure 2a) and TRA (Figure 2b) cells but

not in meningioma cells (Figure 2c), suggesting that in Merlin-negative meningioma, additional mutations may be involved in the regulation of PrP^C [(30-33) and (34)].

PrP^C expression in schwannoma cells is up-regulated by NFκB

To find potential therapeutic targets downstream of Merlin which are involved in increased levels of PrP^C we inhibited two major transcription regulators in schwannoma, ubiquitin E3 ligase CRL4D^{CAF1} using shRNA (35, 36) and NFκB using SN50 inhibitor (8μg/ml, 72 hours) (5). We demonstrate that PrP^C overexpression in schwannoma cells was not affected by CRL4D^{CAF1} shRNA (Figure 2d) but, instead, was significantly decreased upon treatment with NFκB inhibitor SN50 (Figure 2e and Supplementary Figure 2). Thus, in schwannoma PrP^C overexpression is due to Merlin-deficiency and downstream activation of transcription factor NFκB.

PrP^C is released mainly via exosomes from schwannoma cells

A small but significant increase in PrP^C was detected by ELISA in the medium from schwannoma cells compared to Schwann cells (Figure 3a). Since PrP^C can be released via exosomes (20), we first checked the expression of exosome/late endosome marker CD63 in schwannoma and Schwann cells. Figure 3b demonstrates strong overexpression of CD63 in schwannoma compared to Schwann cells, suggesting higher levels of exosomes/late endosomes in these cells (Figure 3b). Additional ELISA experiments, on GFM media containing exosome-free FCS, show that the majority of PrP^C released from schwannoma cells is released via exosomes and only a small portion as free peptides. The levels of exosome-bound PrP^C (Figure 3c, dark grey bar) are 6-fold higher compared to the levels of free PrP^C (Figure 3c, black bar) present in the supernatant fraction left over after exosomes

were isolated. This was compared to 'whole' cell culture medium which was simultaneously collected and run (Figure 3c, medium light grey bar) and fresh GFM as a negative control (Figure 3c, white bar). A similar pattern was demonstrated by Western blotting where clear bands for PrP^C are seen in the exosome fraction (Figure 3d, second row). PrP^C is a glycoprotein and therefore its molecular weight spans between 30 to 37 kDa(10). No band for PrP^C is detectable in the supernatant fraction of medium remaining after exosome isolation collected from schwannoma cells (Figure 3d, third row) which could be due to lower sensitivity of western blot technique compared to ELISA. Furthermore, immunocytochemistry showed co-localisation between PrP^C and CD63 in schwannoma cells (Figure 3e). The levels of free PrP^C are not altered upon treatment of cells with PIPLC (0.2U/ml, 3h) which cleaves PrP^C at the GPI anchor (37) (Figure 3f) and there is no significant difference in the amount of PrP^C released into the cell culture medium after PIPLC treatment (Figure 3g). Thus free PrP^C (Figure 3c) is released by other mechanisms than PIPLC-mediated cleavage. One alternative mechanism is ADAM10 metalloproteinase-mediated cleavage (38). We demonstrate that upon schwannoma cell treatment with ADAM10 inhibitor GI254023X (20µM) for 3 hours the levels of PrP^C increased in cell lysates (Figure 3h) and decreased in culture media (Figure 3i), suggesting that in schwannoma cells PrP^C cleavage and release is mediated at least partially by ADAM10 metalloproteinase.

Reducing PrP^C levels decreases proliferation and survival of schwannoma cells

To investigate functional relevance of PrP^C overexpression we used two methods to reduce PrP^C expression in schwannoma cells; (1) two sets of *PRNP* shRNA lentiviral

particles; (2) an anti-prion agent TCS and both techniques strongly reduced PrP^C expression (Supplementary Figures 3ai, 3aii and 3b). Since, *PRNP* shRNA lentiviral particles from Santa Cruz and *PRNP* shRNA lentivirus from GE Dharmacon displayed similar efficiency for PrP knock down and the decrease of downstream signalling pathways (Supplementary Figures 3ai and 3aii) we combined the data for both shRNA's. We demonstrate that the number of proliferating, Ki67-positive cells, and total cell number (DAPI) were significantly reduced upon treatment with *PRNP* shRNA (Figures 4a, 4i and Supplementary Figure 4a) and TCS (Figures 4b, 4j and Supplementary Figure 4b), as were levels of proliferation marker, cyclin D1 (Figures 4c and 4d). Cells show an increase in apoptosis, detected by cleaved caspase-3 immuno-labelling, upon depletion of PrP^C using both *PRNP* shRNA (Figures 4e and 4i) and TCS (Figures 4f and 4j), and confirmed by Western blot analysis (Figures 4g and 4h). The percentage of alive cells was significantly decreased both using TCS and *PRNP* shRNA (Supplementary Figures 4c and 4d). We also demonstrate that PrP synthetic peptide (amino acid residues 105 - 120 of the human prion protein, N-terminal) (0.8µM, 72 hours) has a cyto-protective role in schwannoma; rescuing cells from hydrogen peroxide H₂O₂ (500µM, 12 hours) mediated cell death (Figure 4k, l m and Supplementary Figure 4e).

Reducing PrP^C levels decreases cell matrix adhesion in schwannoma

Schwannoma display increased cell-matrix adhesion (39) and PrP^C has been shown to affect cell adhesion via interactions with laminin and the neural cell adhesion molecule (NCAM) in hippocampal neurons (10). Therefore, we investigated whether reducing levels of PrP^C would decrease cell adhesion to the laminin/poly-lysine cell matrix. After knockdown of *PRNP* mRNA, cells were less capable of adhering to the

cell matrix (Figure 4n). The same reduction in adhesion was also seen upon depletion of PrP^C using TCS (Figure 4o), n=3). These data suggest that PrP^C is involved in the pathological cell-matrix adhesion of schwannoma.

Decreasing expression of PrP^C alters activity and expression of several key signalling pathways known to be involved in schwannoma development

We next analysed whether signalling via the key pathways (PI3K/AKT, ERK1/2 and FAK) known to be involved in schwannoma proliferation, survival and cell-matrix adhesion were affected by reducing PrP^C. The MAPK pathway has previously been linked to PrP^C signalling (40).

ERK. Levels of total ERK1/2 are significantly reduced upon treatment with *PRNP* shRNA and high concentrations of TCS (Figures 5a and 5b, dark grey bars). Active pERK1/2 expression (light grey bars), was also significantly reduced with *PRNP* shRNA and at both 100µM and 500µM TCS inhibitor concentrations (Figures 5a and 5b, light grey bars).

AKT. Although a slight tendency for total AKT to decrease upon PrP knockdown and TCS treatment, the values are non-significant (Figures 5c and 5d dark grey bars). Levels of active pAKT, however, significantly decrease with *PRNP* shRNA and TCS (Figures 5c and 5d, light grey bars).

FAK. Total FAK is significantly reduced after *PRNP* knockdown and upon treatment with high levels (500µM) of TCS (Figures 5e and 5f, dark grey bars). Levels of auto-phosphorylated FAK^{Y397} are significantly reduced with *PRNP* shRNA and also at all concentrations of TCS (Figures 5e and 5f, light grey bars).

Thus PrP^C is linked to increased expression and activation of ERK1/2, FAK and the activation of PI3K/AKT pathway in schwannoma cells which are known to be

involved in schwannoma development (18, 19).

Treatment with PrP peptide and overexpressing PrP^C increases Schwann cell proliferation and expression of c-Jun

Next we looked at the effects of increasing PrP^C levels in Schwann cells to see if a pathological phenotype could be induced. First, we used a PrP synthetic peptide to mimic the effect of free PrP in cell culture media (41, 42). Schwann cells were stimulated for 6 days with 0.8 μ M of PrP peptide before looking at levels of proliferation (Ki67) and expression of the proto-oncogene c-Jun which is involved in Schwann cells proliferation and overexpressed/activated in schwannoma via c-Jun N-terminal kinase (JNK) leading to increased tumour proliferation and survival (43). Both the number of Ki67 positive cells (Figure 6a, red staining) and c-Jun positive cells (Figure 6b, green staining) increased in cells treated with PrP (105 – 120) peptide compared to untreated cells in GFM media. Cell morphology examined by the cytoskeletal F-actin marker phalloidin, showed that Schwann cells looked more like schwannoma tumour cells with an increase in cell spreading and membrane ruffling after treatment with PrP peptide (0.8 μ M) for 6 days and two weeks compared to untreated cells (Figure 6c). Cell area was measured using ImageJ software in n=52 cells (6 days) and in n=50 cells (2 weeks) (Figure 6c right panel). Next, we checked if PrP (105 – 120) peptide treatment had caused the transformation of endogenous PrP^C protein into protease-resistant PrP^{Res} (44). Cells were lysed either in the presence of protease inhibitors or instead with proteinase K after being treated for six days with PrP (105 – 120) peptide. Results show that cells still expressed normal protease-sensitive PrP^C after treated with PrP (105 – 120) (Figure 6d).

Moreover, we produced *PRNP* overexpressing lentiviruses using a pLenti6.2/V5-DEST plasmid (Supplementary Figure 5), to overexpress full length PrP^C in Schwann cells. DNA from *PRNP* coding region (NCBI Reference Sequence: NG_009087.1) from two separate transformation starter colonies (O/E1B, Figure 6e and O/E2B, Supplementary Figure 6) were used. Western blotting shows that overexpression of PrP^C significantly increases levels of both Cyclin D1 and c-Jun in Schwann cells compared to the GFP-containing control (Figures 6e-g and Supplementary Figure 6). These data confirm our results obtained using *PRNP* shRNA and TCS in schwannoma cells indicating the crucial role of PrP^C in schwannoma development.

PrP^C employs LR/37/67kDa to regulate cellular functions

Membrane-bound as well as externally added PrP^C has been previously shown to interact with the LR/37/67kDa observed in murine N2a neuroblastoma and hypothalamic neuronal mouse GT1 cell lines (23). We demonstrate that LR/37/67kDa is expressed in schwannoma cells (Supplementary Figure 7a).

LR/37/67kDa co-localises with PrP^C in the cytosol, cell membrane and membrane ruffles in permeabilised schwannoma cells (Figure 7a) and in membrane ruffles of non-permeabilised cells (Figure 7b). Additionally, LR/37/67kDa interacts with PrP^C in schwannoma cell lysates demonstrated by co-immunoprecipitation using both proteins as bait (Figures 7c and 7d). Stimulation of starved schwannoma cells with synthetic PrP (105 – 120) peptide for 24 hours increased expression of cyclin D1 (Figures 7e, light grey bars and 7i, row 1) and, after one hour increased activation of ERK, AKT and FAK (Figures 7f-h, light grey bars and 7i, rows 2-4) which was reverted using LR/37/67kDa shRNA (Figures 7e-h, dark grey bars and 7i, rows 1-4). We used a mock PrP peptide to show that the effect of the synthetic PrP (105 – 120)

peptide is specific (Supplementary Figure 7b).

Discussion

In the current study we found, that PrP^C is expressed at protein level in Merlin-deficient human primary schwannoma cells and tissues compared to controls. Surprisingly, this increase is due to upregulated *PRNP* transcription and translation *per se* and not by, as previously reported, decreased proteasomal degradation (27). We have also revealed that PrP^C overexpression translates to other Merlin-deficient tumours, such as human Merlin-negative mesothelioma cell line TRA and human Merlin-negative grade I meningioma cells/tissues. Interestingly, Merlin re-introduction strongly reduced PrP^C levels schwannoma and TRA cells but not in meningioma. This could be due to mutation in additional tumour suppressors, observed in Merlin-deficient meningiomas, such DAL-1 (differentially expressed in adenocarcinoma of the lung)/4.1B protein (30, 31, 45), BCR (breakpoint cluster region) (32), or SMARCB1 (46) which requires further investigations.. We also revealed that PrP^C overexpression in schwannoma cells is regulated by transcription factor NFκB which we previously shown is regulated by Merlin (6). NFκB has been shown to be involved in PrP-mediated invasion and migration in breast cancer cells (47) and can be activated by PrP peptide PrP(106-126) in human monocyte-derived dendritic cells (48), however its role in the regulation of PrP^C expression has never been reported and importantly opens a new therapeutic angle.

The pathological relevance of PrP^C overexpression is emphasised by its increased release from schwannoma cells compared to Schwann cells which suggest an effect via auto- and/or paracrine mechanisms (49).. Interestingly, PrP^C is released both as free (cleaved) peptide,, by ADAM10 metalloproteinase cleavage, and in association with exosomes. Although, there are previous observations showing exosome-mediated release of PrP^C from various cell types such as activated

platelets, rat and mouse cortical neurons and mouse neuroblastoma cells (50-52) our findings demonstrate this mechanism for the first time in human primary tumour cells.

Concerning the mechanism of action, we have shown that PrP^C contributes to schwannoma development by increasing the expression of the cell cycle regulator cyclin D1 resulting in pathologically enhanced proliferation. Although one study performed on cortical neurones showed no effect of PrP on cyclin D1 levels (53), most studies agree with our findings (54). PrP^C-deficient fibroblasts displayed a significant down-regulation of cyclin D1 (54) and, in gastric carcinoma, PrP^C accelerated the G1/S phase transition via induction of cyclin D1 through PI3K/AKT pathway (55), supporting our finding on the role of PrP^C in cyclin D1 expression and AKT activation. We also demonstrate that ERK1/2 activation, which is involved in schwannoma proliferation (56), is potentiated by PrP^C. This is in agreement with other studies reporting the role of MAPK pathway in PrP^C-induced neuritogenesis (53). PrP^C in schwannoma cells contributes to increased pathological survival of these cells, which parallels the majority of work in the field (57). However, a link between PrP^C overexpression and increased cell death via caspase-3 has been reported in murine TSM1 neuronal cells and HEK293T cells (57). Importantly, we found that PrP^C has cytoprotective effect in schwannoma, since pre-treatment with PrP (105 – 120) peptide rescued schwannoma cells from H₂O₂ oxidative stress-mediated cell death (58).

PrP^C plays a role in cell matrix adhesion of schwannoma cells in accordance with previous findings revealing PrP^C interaction with adhesion molecules such as LR/37/67kDa (59) and integrins (60). FAK, a component of focal adhesion complexes is overexpressed in schwannoma (5). Previous findings have shown that

PrP^C silencing induces focal adhesion remodelling (61), now our findings strengthen the link between PrP^C and FAK as we demonstrate that reducing levels of PrP^C decreases cell-matrix adhesion as well the activity and expression of FAK. Essentially, we have shown by knock down experiments that the PrP^C-mediated activation of cyclin D1, ERK1/2, AKT and FAK pathways is due to PrP^C interaction with LR/37/67kDa, suggesting that LR/37/67kDa acts as a cell surface receptor for PrP^C in schwannoma cells.

These results were complemented by either treating Schwann cells with synthetic PrP (105 – 120) peptide or by overexpressing *PRNP*. Both treatments dramatically changed Schwann cells' morphology, increased cell proliferation and the expression of the major regulator of Schwann cell proliferation c-Jun (62-64).

In summary, we demonstrate that PrP^C protein is overexpressed in human schwannoma cells and tissues and plays a part in schwannoma proliferation, cell matrix adhesion and survival. Importantly, PrP^C overexpression was also observed in human mesothelioma cell line TRA and in human grade I meningioma cells and tissues. PrP^C is released in schwannoma cells by exosomes and as free peptides which may contribute to tumourigenesis by autocrine or/and paracrine signalling. PrP^C interacts with and acts via LR/37/67kDa to activate cyclin D1, ERK1/2, PI3K/AKT and FAK in schwannoma cells. Thus, PrP^C and LR/37/67kDa, are good potential therapeutic targets for schwannoma and other Merlin-deficient tumours. PrP^C-mediated signalling can be inhibited in two main ways: firstly, by targeting PrP^C directly using humanized anti-PrP antibody PRN100 (MRC Prion Unit for sporadic Creutzfeldt-Jakob disease) (24) or using the proteasome inhibitor (targeting NFκB) Bortezomib (FDA approved for multiple myeloma treatment) (25); secondly, by blocking LR/37/67kDa using inhibitors such as anti-LR/37/67kDa antibodies (22),

polysulfated glycans (59), small interfering RNAs (65) and LR/37/67kDa-Laminin interaction inhibitor NSC47924 (23).

Material and Methods

Cell cultures

After informed consent, schwannoma and meningioma grade I specimens were collected from surgical procedures and normal nerve from post-mortem donors. Schwannoma and Schwann cells were cultured in growth factor medium (GFM): DMEM; 100U/ml pen/strep; 2.5 µg/ml Insulin (Thermo Fisher Scientific, MA, USA); 0.5µM Forskolin (Tocris, Bristol, UK); 10% FBS, 2.5µg/ml Amphotericin (Sigma, MO, USA); 10nM β 1 heregulin; 0.5mM 3-isobutyl-1-methylxanthine (IBMX) (Bio-Techne, MN, USA) at 37°C in 10% CO₂ (66). Meningioma cells were grown in DMEM containing glucose (4.5 g/l), 10% FBS, 100 U/ml penicillin/streptomycin and 1% glutamine. Human meningeal cells (HMC, Sciencell, CA, USA) were grown in the recommended HMC medium (Sciencell) at 37 °C and 5% CO₂. Human mesothelioma cell lines HIB and TRA were cultured in DMEM, containing 10% FBS and 100 U/ml pen/strep at 37 °C and 5% CO₂. (39). Human schwannoma and meningioma grade I primary cells (passages 1-4) and tissues used in this study are Merlin-negative (Supplementary Figure 1a and Figure 1k). All Schwann cell cultures are S100 positive (Supplementary Figure 1b). The n number states number of biological repeats.

Chemicals

TCS anti-prion agent 13 was from Tocris Bioscience (67), Proteinase K, MG132, Cycloheximide (CHX), Actinomycin D (Act. D), Phosphatidylinositol Phospholipase C

(PIPLC) and DAPI were from Sigma (MO, USA). Synthetic PrP peptide (AA105-120, KTNMKHMAGAAAAGAVVGGLG) was from AbD Serotec (Bio-Rad, CA, USA) and mock peptide (NGAKALMGGHGATKVMVGAAA) was kindly provided by Dr. M. Salmona of the Istituto Ricerche Farmcologiche Mario Negri, Italy. NF κ B inhibitor SN50 was from Calbiochem (La Jolla, CA, USA) and ADAM 10 inhibitor GI254023X from Sigma (Sigma, MO, USA).

Exosome Isolation

Cells were cultured for 7 days in medium containing exosome-free FBS (Gibco). Exosomes were isolated using total exosome isolation reagent (Thermo Fisher Scientific) according to the manufacturer's protocol.

Enzyme-linked Immunosorbent assay

Cells were cultured for 3 days in GFM; medium was collected and concentrated 10x using AmiconUltra® filters (Merck Millipore, MA, USA). PrP^C was detected using Prion Protein (*PRNP*) ELISA kit (CUSABIO, Hubei, China, ABIN821046) according to the manufacturer's protocol.

Immunocytochemistry

Immunocytochemistry was performed as described in Flaiz et. al 2009 (68) using anti-human-PrP^C (Santa Cruz Biotechnologies, CA, USA), anti-CD63 (Merck Millipore), anti-c-Jun (Cell Signalling Technology, MA, USA) and anti- LR/37/67kDa (Novus Biologicals, CO, USA) antibodies. Alexa Fluor 488-labeled phalloidin (Life Technologies, CA, USA) was used to visualize actin filaments (1:100; Molecular Probes, Eugene, OR). Multitrack imaging was performed using a Zeiss Confocal

LSM510.

Immunohistochemistry

Tissue sections were pre-treated with EDTA buffer at pH 9 for 30 min, before overnight incubation with the anti-PrP^C12F10 (1:1000; Bioquote, York, UK). Detection was performed with the Vectastain Universal Elite ABC kit (Vector Laboratories, Peterborough, UK).

Proliferation and survival assays

Proliferation and survival assays were carried out using immunofluorescence, after 72 hours incubation with viral particles or treatment with TCS prion inhibitor, with anti-Ki67 (Dako) and anti-cleaved caspase-3 (Cell Signalling Technologies) antibodies. Multitrack imaging was performed using a Zeiss Confocal LSM510.

MTS test

Schwannoma cells were pre-treated with 0.8µM of PrP peptide for 72 hours followed by addition of H₂O₂ (500µM) for additional 12 hours. MTS test was performed according to manufacturer's protocol (Promega).

De-glycosylation assay

Cell lysates were treated with 5% sodium dodecyl sulphate, 1M Dithiothreitol, 0.5M Sodium phosphate buffer (pH7.5), 10% Triton X-100 and PNGase F (Promega, WI, USA) at 37°C for 1-3h before being run on SDS-PAGE.

Adhesion assay

Cells were seeded onto pre-coated 96-well plates for three hours using different

conditions: DMEM and 20µM, 100µM and 500µM anti-prion agent TCS.. *PRNP* and scramble shRNA were selected prior to being split and plated. Cells were counted and adhesion assay was performed as described previously in Utermark et al (39).

Merlin re-introduction

Merlin (*NF2*) wild type (recombinant adenovirus AdNF2) and control GFP-containing vector adenoviruses were a kind gift from J. Testa (29). Cells were treated with virus for 24 hours and then incubated with fresh GFM for additional 24 hours and lysed.

Knock-down experiments using shRNA's

Cells were incubated with shRNA and scramble control viruses for 48 hours, before selection with puromycin for 72 hours. *PRNP* shRNA lentiviral particles (Santa Cruz Biotechnologies); pool of three to five expression constructs each encoding a different, target-specific 19-25nt region of PrP^C were used to knock down *PRNP* expression plus control hairpin shRNA particles. Results were combined with lentivirus made from TRCN0000083488, part of a TRC *PRNP* shRNA, glycerol set (GE Dharmacon, CO, USA). 37/67kDa Laminin Receptor shRNA (h) lentiviral particles (Santa Cruz Biotechnologies) were used to knock down LR/37/67kDa (h) (pool of three to five expression constructs that encode a 19-25 nt (plus hairpin)).

***PRNP* overexpressing clone**

DNA from *PRNP* coding region (NCBI Reference Sequence: NG_009087.1) from two separate transformation starter colonies (1B and 2B) were cloned into a pLenti6 overexpressing vector (Invitrogen). Lentiviral particles were produced by transfection into HEK293FT cells using Eugene 6 (Promega).

Co-Immunoprecipitation

Primary human schwannoma cells (1mg) lysed in low-salt buffer was incubated overnight with 1µg normal IgG (Santa Cruz Biotechnologies) or 1µg anti-PrP antibody (Sigma), 37/67kDa anti-laminin receptor (Abcam) in the presence of protein G agarose beads (GE healthcare).

Western Blotting

After Western blotting (39) membranes were incubated with primary antibodies: anti-PrP, anti-cleaved caspase-3, anti-cyclin D1, anti-total MAPK/ERK1/2, anti-total FAK, anti-pFAK Tyr³⁹⁷, anti-total AKT, anti-pAKT Ser⁴⁷³, anti- active MAPK; anti-pThr¹⁸³-pTyr¹⁸⁵-ERK1/2; Promega), anti-37/67kDa laminin receptor (Novus Biologicals), anti-CD63 (Merck Millipore), second anti-PrP^C (AbD Serotec; N-terminus) and anti-Merlin antibody (Cell Signalling) (D1B8 clone cat. number 6995). Horseradish peroxidase-conjugated secondary antibodies (BioRad) and chemiluminescence (Thermo Fisher Scientific) were used for detection. GAPDH (Merck Millipore) was used as a loading control. Densities were quantified using FluorS-Multi-Imager with Quantity One software (Biorad).

Statistics

Unpaired student's two-tailed t-test was used in all pairwise comparisons and analysis of variance (one-way Anova) followed by post-hoc tukey test for multiple comparisons. F-test was used to compare variances and standard deviations between the groups compared to meet the assumption of the statistical test. Experiments were performed in at least triplicates using at least three different batches of cells from different individuals. In some experiments samples from more

than three different individuals were used. ns (not significant) $p > 0.05$, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. In figures mean \pm SEM is given.

Conflict of interest

The authors declare no conflict of interests.

References

1. Hanemann CO. Magic but treatable? Tumours due to loss of merlin. *Brain*. 2008;131(Pt 3):606-15.
2. Petrilli AM, Fernandez-Valle C. Role of Merlin/NF2 inactivation in tumor biology. *Oncogene*. 2016;35(5):537-48. Epub 2015/04/22.
3. Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, et al. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. *Am J Med Genet A*. 2012;158A(1):24-41. Epub 2011/12/06.
4. Rosenbaum C, Kluwe L, Mautner VF, Friedrich RE, Mueller HW, Hanemann CO. Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients. *Neurobiology of disease*. 1998;5(1):55-64.
5. Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton DA, et al. Axl/Gas6/NFkappaB signalling in schwannoma pathological proliferation, adhesion and survival. *Oncogene*. 2014;33(3):336-46. Epub 2013/01/16.
6. Ammoun S, Schmid MC, Zhou L, Hilton DA, Barczyk M, Hanemann CO. The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours. *Mol Oncol*. 2014. Epub 2014/09/14.
7. Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, et al. Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4(DCAF1) in the Nucleus. *Cell*. 2010;140(4):477-90.
8. Zhou L, Ercolano E, Ammoun S, Schmid MC, Barczyk MA, Hanemann CO. Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/beta-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways. *Neoplasia*. 2011;13(12):1101-12. Epub 2012/01/17.
9. Hanemann CO, Bartelt-Kirbach B, Diebold R, Kampchen K, Langmesser S, Utermark T. Differential gene expression between human schwannoma and control Schwann cells. *NeuropatholApplNeurobiol*. 2006;32(6):605-14.
10. Westergaard L, Christensen HM, Harris DA. The cellular prion protein (PrP(C)): its physiological function and role in disease. *Biochim Biophys Acta*. 2007;1772(6):629-44. Epub 2007/04/25.
11. Ford MJ, Burton LJ, Morris RJ, Hall SM. Selective expression of prion protein in peripheral tissues of the adult mouse. *Neuroscience*. 2002;113(1):177-92.
12. Steele AD, Emsley JG, Ozdinler PH, Lindquist S, Macklis JD. Prion protein

(PrPc) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis. *Proceedings of the National Academy of Sciences of the United States of America*. 2006;103(9):3416-21. Epub 2006/02/24.

13. Bremer J, Baumann F, Tiberi C, Wessig C, Fischer H, Schwarz P, et al. Axonal prion protein is required for peripheral myelin maintenance. *Nature neuroscience*. 2010;13(3):310-8. Epub 2010/01/26.

14. Stella R, Massimino ML, Sandri M, Sorgato MC, Bertoli A. Cellular prion protein promotes regeneration of adult muscle tissue. *Molecular and cellular biology*. 2010;30(20):4864-76. Epub 2010/08/04.

15. Santos TG, Lopes MH, Martins VR. Targeting prion protein interactions in cancer. *Prion*. 2015;9(3):165-73. Epub 2015/06/26.

16. Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, Brentani RR. Physiology of the prion protein. *Physiological reviews*. 2008;88(2):673-728. Epub 2008/04/09.

17. Zeng L, Zou W, Wang G. Cellular prion protein (PrP(C)) and its role in stress responses. *International journal of clinical and experimental medicine*. 2015;8(5):8042-50. Epub 2015/07/30.

18. Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. *Cancer Res*. 2008;68(13):5236-45.

19. Ammoun S, Schmid MC, Zhou L, Ristic N, Ercolano E, Hilton DA, et al. Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival. *Oncogene*. 2011. Epub 2011/09/06.

20. Fevrier B, Vilette D, Archer F, Loew D, Faigle W, Vidal M, et al. Cells release prions in association with exosomes. *Proceedings of the National Academy of Sciences of the United States of America*. 2004;101(26):9683-8. Epub 2004/06/24.

21. Guillot-Sestier MV, Sunyach C, Druon C, Scarzello S, Checler F. The alpha-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo. *The Journal of biological chemistry*. 2009;284(51):35973-86. Epub 2009/10/24.

22. Zuber C, Knackmuss S, Rey C, Reusch U, Rottgen P, Frohlich T, et al. Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseases. *Molecular immunology*. 2008;45(1):144-51. Epub 2007/06/20.

23. Sarnataro D, Pepe A, Altamura G, De Simone I, Pesapane A, Nitsch L, et al. The 37/67 kDa laminin receptor (LR) inhibitor, NSC47924, affects 37/67 kDa LR cell surface localization and interaction with the cellular prion protein. *Scientific reports*. 2016;6:24457. Epub 2016/04/14.

24. Klyubin I, Nicoll AJ, Khalili-Shirazi A, Farmer M, Canning S, Mably A, et al. Peripheral administration of a humanized anti-PrP antibody blocks Alzheimer's disease Aβ synaptotoxicity. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2014;34(18):6140-5. Epub 2014/05/03.

25. Lin Y, Bai L, Chen W, Xu S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. *Expert opinion on therapeutic targets*. 2010;14(1):45-55. Epub 2009/12/17.

26. Yap YH, Say YH. Resistance against apoptosis by the cellular prion protein is dependent on its glycosylation status in oral HSC-2 and colon LS 174T cancer cells. *Cancer letters*. 2011;306(1):111-9. Epub 2011/03/29.

27. Ma J, Lindquist S. Wild-type PrP and a mutant associated with prion disease

- are subject to retrograde transport and proteasome degradation. *Proceedings of the National Academy of Sciences of the United States of America*. 2001;98(26):14955-60. Epub 2001/12/14.
28. Deguen B, Goutebroze L, Giovannini M, Boisson C, van der NR, Jaurand MC, et al. Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene. *IntJCancer*. 1998;77(4):554-60.
 29. Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG, et al. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. *Molecular and cellular biology*. 2005;25(6):2384-94.
 30. Gerber MA, Bahr SM, Gutmann DH. Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling. *Cancer research*. 2006;66(10):5295-303. Epub 2006/05/19.
 31. Nunes F, Shen Y, Niida Y, Beauchamp R, Stemmer-Rachamimov AO, Ramesh V, et al. Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma. *Cancer genetics and cytogenetics*. 2005;162(2):135-9. Epub 2005/10/11.
 32. Wozniak K, Piaskowski S, Gresner SM, Golanska E, Bieniek E, Bigoszezewska K, et al. BCR expression is decreased in meningiomas showing loss of heterozygosity of 22q within a new minimal deletion region. *Cancer genetics and cytogenetics*. 2008;183(1):14-20. Epub 2008/05/14.
 33. van den Munckhof P, Christiaans I, Kenter SB, Baas F, Hulsebos TJ. Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. *Neurogenetics*. 2012;13(1):1-7. Epub 2011/11/01.
 34. Yuzawa S, Nishihara H, Tanaka S. Genetic landscape of meningioma. *Brain tumor pathology*. 2016;33(4):237-47. Epub 2016/09/15.
 35. Li W, Giancotti FG. Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4 (DCAF1). *Cell cycle*. 2010;9(22):4433-6. Epub 2010/11/19.
 36. Zhou L, Hanemann CO. Merlin, a multi-suppressor from cell membrane to the nucleus. *FEBS letters*. 2012;586(10):1403-8. Epub 2012/05/19.
 37. Parkin ET, Watt NT, Turner AJ, Hooper NM. Dual mechanisms for shedding of the cellular prion protein. *The Journal of biological chemistry*. 2004;279(12):11170-8. Epub 2004/01/09.
 38. Altmeppen HC, Prox J, Puig B, Kluth MA, Bernreuther C, Thurm D, et al. Lack of α -disintegrin-and-metalloproteinase ADAM10 leads to intracellular accumulation and loss of shedding of the cellular prion protein in vivo. *Molecular neurodegeneration*. 2011;6:36. Epub 2011/05/31.
 39. Utermark T, Kaempchen K, Hanemann CO. Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins. *Brain Pathol*. 2003;13(3):352-63.
 40. Weise J, Doeppner TR, Muller T, Wrede A, Schulz-Schaeffer W, Zerr I, et al. Overexpression of cellular prion protein alters postischemic Erk1/2 phosphorylation but not Akt phosphorylation and protects against focal cerebral ischemia. *Restorative neurology and neuroscience*. 2008;26(1):57-64. Epub 2008/04/24.
 41. Arsenault RJ, Li Y, Potter A, Griebel PJ, Kusalik A, Napper S. Induction of ligand-specific PrP (C) signaling in human neuronal cells. *Prion*. 2012;7(1). Epub 2012/08/25.
 42. Zhou XM, Xu GX, Zhao DM. In vitro effect of prion peptide PrP 106-126 on

- mouse macrophages: Possible role of macrophages in transport and proliferation for prion protein. *Microbial pathogenesis*. 2008;44(2):129-34. Epub 2007/10/02.
43. Parkinson DB, Bhaskaran A, rthur-Farraj P, Noon LA, Woodhoo A, Lloyd AC, et al. c-Jun is a negative regulator of myelination. *JCell Biol*. 2008;181(4):625-37.
 44. Gu Y, Fujioka H, Mishra RS, Li R, Singh N. Prion peptide 106-126 modulates the aggregation of cellular prion protein and induces the synthesis of potentially neurotoxic transmembrane PrP. *The Journal of biological chemistry*. 2002;277(3):2275-86. Epub 2001/10/30.
 45. Robb VA, Gerber MA, Hart-Mahon EK, Gutmann DH. Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression. *Oncogene*. 2005;24(11):1946-57. Epub 2005/02/03.
 46. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. *Science*. 2013;339(6123):1077-80. Epub 2013/01/26.
 47. Bourteele S, Oesterle K, Weinzierl AO, Paxian S, Riemann M, Schmid RM, et al. Alteration of NF-kappaB activity leads to mitochondrial apoptosis after infection with pathological prion protein. *Cellular microbiology*. 2007;9(9):2202-17. Epub 2007/06/19.
 48. Bacot SM, Lenz P, Frazier-Jessen MR, Feldman GM. Activation by prion peptide PrP106-126 induces a NF-kappaB-driven proinflammatory response in human monocyte-derived dendritic cells. *Journal of leukocyte biology*. 2003;74(1):118-25. Epub 2003/07/02.
 49. Guo BB, Bellingham SA, Hill AF. Stimulating the Release of Exosomes Increases the Intercellular Transfer of Prions. *The Journal of biological chemistry*. 2016;291(10):5128-37. Epub 2016/01/16.
 50. Robertson C, Booth SA, Beniac DR, Coulthart MB, Booth TF, McNicol A. Cellular prion protein is released on exosomes from activated platelets. *Blood*. 2006;107(10):3907-11. Epub 2006/01/26.
 51. Faure J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B, et al. Exosomes are released by cultured cortical neurones. *Molecular and cellular neurosciences*. 2006;31(4):642-8. Epub 2006/02/01.
 52. Alais S, Simoes S, Baas D, Lehmann S, Raposo G, Darlix JL, et al. Mouse neuroblastoma cells release prion infectivity associated with exosomal vesicles. *Biology of the cell*. 2008;100(10):603-15. Epub 2008/04/22.
 53. Lopes JP, Oliveira CR, Agostinho P. Cdk5 acts as a mediator of neuronal cell cycle re-entry triggered by amyloid-beta and prion peptides. *Cell cycle*. 2009;8(1):97-104. Epub 2009/01/23.
 54. Satoh J, Kuroda Y, Katamine S. Gene expression profile in prion protein-deficient fibroblasts in culture. *The American journal of pathology*. 2000;157(1):59-68. Epub 2000/07/06.
 55. Liang J, Pan Y, Zhang D, Guo C, Shi Y, Wang J, et al. Cellular prion protein promotes proliferation and G1/S transition of human gastric cancer cells SGC7901 and AGS. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2007;21(9):2247-56. Epub 2007/04/06.
 56. Ammoun S, Ristic N, Matthies C, Hilton DA, Hanemann CO. Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244. *NeurobiolDis*. 2010;37:141-6.
 57. Godsave SF, Peters PJ, Wille H. Subcellular distribution of the prion protein in sickness and in health. *Virus research*. 2015;207:136-45. Epub 2015/02/17.
 58. Singh N, Singh A, Das D, Mohan ML. Redox control of prion and disease

- pathogenesis. *Antioxidants & redox signaling*. 2010;12(11):1271-94. Epub 2009/10/07.
59. Gauczynski S, Peyrin JM, Haik S, Leucht C, Hundt C, Rieger R, et al. The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. *The EMBO journal*. 2001;20(21):5863-75. Epub 2001/11/02.
 60. Watts JC, Westaway D. The prion protein family: diversity, rivalry, and dysfunction. *Biochim Biophys Acta*. 2007;1772(6):654-72. Epub 2007/06/15.
 61. Loubet D, Dakowski C, Pietri M, Pradines E, Bernard S, Callebaut J, et al. Neuritogenesis: the prion protein controls beta1 integrin signaling activity. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2012;26(2):678-90. Epub 2011/11/01.
 62. Carimalo J, Cronier S, Petit G, Peyrin JM, Boukhtouche F, Arbez N, et al. Activation of the JNK-c-Jun pathway during the early phase of neuronal apoptosis induced by PrP106-126 and prion infection. *The European journal of neuroscience*. 2005;21(9):2311-9. Epub 2005/06/04.
 63. Parkinson DB, Bhaskaran A, Droggiti A, Dickinson S, D'Antonio M, Mirsky R, et al. Krox-20 inhibits Jun-NH2-terminal kinase/c-Jun to control Schwann cell proliferation and death. *JCell Biol*. 2004;164(3):385-94.
 64. Shivane A, Parkinson DB, Ammoun S, Hanemann CO. Expression of c-Jun and Sox-2 in human schwannomas and traumatic neuromas. *Histopathology*. 2013;62(4):651-6. Epub 2013/02/01.
 65. Pflanzner T, Petsch B, Andre-Dohmen B, Muller-Schiffmann A, Tschickardt S, Weggen S, et al. Cellular prion protein participates in amyloid-beta transcytosis across the blood-brain barrier. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. 2012;32(4):628-32. Epub 2012/02/02.
 66. Rosenbaum C, Kluwe L, Mautner VF, Friedrich RE, Muller HW, Hanemann CO. Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients. *NeurobiolDis*. 1998;5(1):55-64.
 67. Kimata A, Nakagawa H, Ohyama R, Fukuuchi T, Ohta S, Doh-ura K, et al. New series of antiprion compounds: pyrazolone derivatives have the potent activity of inhibiting protease-resistant prion protein accumulation. *Journal of medicinal chemistry*. 2007;50(21):5053-6. Epub 2007/09/14.
 68. Flaiz C, Ammoun S, Biebl A, Hanemann CO. Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma. *Brain Pathol*. 2009;19(1):27-38.
 69. Hilton DA, Shivane A, Kirk L, Bassiri K, Enki DG, Hanemann CO. Activation of multiple growth factor signalling pathways is frequent in meningiomas. *Neuropathology : official journal of the Japanese Society of Neuropathology*. 2016;36(3):250-61. Epub 2015/11/11.
 70. Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F, Proksch E, et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. *Proceedings of the National Academy of Sciences of the United States of America*. 2005;102(26):9182-7. Epub 2005/06/17.

Acknowledgments

The authors thank Mario Salmona for mock PrP peptide and Joseph Testa for Merlin adenovirus. This work was supported by The Laura Crane Youth Cancer Trust.

Figure legends

Figure 1.

Expression of PrP^C in human Schwann cells (NF2+/+) and schwannoma cells (NF2-/-). **(a-c)** PrP is overexpressed in schwannoma compared to Schwann cells (a, n=5; b, n=20; c, n=5). PrP localises to the membrane ruffles and throughout the cytosol of schwannoma cells (a, n=5). **(d)** PrP^C in schwannoma is degraded upon treatment with proteinase K (PK), n=5. **(e left and right)** Glycosylation patterns of PrP^C between Schwann cells (NF2+/+) and schwannoma (NF2-/-) cells show no difference in the ratio of mono- and un-glycosylated PrP^C between these two cell types (n=5). **(f and g)** Treatment of schwannoma cells with actinomycin D (ActD) (f, n=5) and with cycloheximide (CHX) (g, n=6) reduces PrP^C expression in schwannoma cells. **(h)** Inhibition of proteasomal degradation by MG132 increases PrP^C levels in schwannoma cells, n=6. **(i)** PrP^C is strongly overexpressed in human Merlin-deficient mesothelioma cell line TRA compared to human Merlin-positive mesothelioma cell line HIB (n=3). **(j and k)** Human Merlin-negative (Fish analysis of chromosome 22q loss (69)) meningioma grade I tissues (j, n=10) and primary cells (k, n=8) strongly overexpress PrP^C compared to normal Merlin-positive meningeal tissues and primary cells. Data are presented as \pm SEM (Ns p>0.05, *p<0.05, **p<0.01, ***p<0.00).

Figure 2.

The regulation of PrP^C expression. **(a-c)** Adenoviral reintroduction of the Merlin/NF2 gene into human Merlin-negative schwannoma (a, n=3), Merlin-negative TRA (b, n=3) and Merlin-negative meningioma grade I cells (c, n=3) significantly decreased PrP^C expression in schwannoma and TRA cells but not in meningioma cells. **(d)** CRL4D^{CAF1} shRNA has no effect on PrP^C expression. **(e)** NF κ B inhibitor SN50

significantly decreased PrP^C levels. Data are presented as \pm SEM (Ns $p>0.05$, * $p<0.05$, ** $p<0.01$, *** $p<0.001$).

Figure 3.

PrP^C is released from schwannoma cells via exosomes. **(a)** PrP^C is released significantly more from schwannoma cells (NF2^{-/-}, dark grey bar) compared to Schwann cells (NF2^{+/+}, light grey bar) detected by ELISA, $n=3$. **(b)** Schwannoma cells (NF2^{-/-}) display strong expression of exosome/late endosome marker CD63 compared to Schwann cells (NF2^{+/+}), $n=3$. **(c and d)** The majority of PrP^C released from schwannoma cells is released via exosomes (c, dark grey bar, $n=3$ and d second row, $n=5$), only a very small amount is released as free peptide in the supernatant (c, black bar, $n=3$). **(e)** PrP^C co-localises to late endosome/exosome marker CD63 in schwannoma cells, $n=3$. **(f and g)** Treatment of schwannoma cells with PIPLC showed no change to the levels of PrP^C within cells (f, $n=3$) and PrP^C released from cells (g, $n=3$). **(h and i)** In schwannoma cells PrP^C cleavage and release is mediated by ADAM10 metalloproteinase. Cells were treated with ADAM10 inhibitor GI254023X (20 μ M) for 3 hours and PrP^C levels were detected by Western blotting in cell lysates (h, $n=5$) and by ELISA in culture media (i). E Cadherin is used as a control for ADAM10 inhibition (70). Phalloidin visualise actin. Data are presented as \pm SEM (ns $p>0.05$, * $p<0.05$, ** $p<0.01$, *** $p<0.001$). Multi-track, z-stack confocal microscopy was used for immunofluorescence (d and e).

Figure 4.

The role of PrP^C in schwannoma proliferation, survival and cell-matrix adhesion. **(a and i)** Number of Ki-67-positive nuclei reduces upon depletion of PrP^C using *PRNP* shRNA, $n=5$. **(b and j)** Number of Ki-67-positive nuclei reduces upon depletion of

PrP^C using anti-prion agent TCS, n=5. **(c and d)** levels of Cyclin D1 significantly reduce with *PRNP* shRNA (c, n=5) and TCS treatment (d, n=5). **(e and i)** Reducing PrP^C levels significantly increases expression of cleaved caspase-3 using *PRNP* shRNA, n=3. **(f and j)** Reducing PrP^C levels using TCS significantly increases expression of cleaved caspase-3, n=3. **(g and h)** Both *PRNP* shRNA (g, n=5) and TCS (h, n=5) reduce PrP^C levels and significantly increase expression of cleaved caspase-3. **(k, l and m)** PrP synthetic peptide (KTNMKH MAGAAAAGAC corresponding to amino acid residues 105 - 120 of the human prion protein, N-terminal) rescues schwannoma cells from H₂O₂-mediated cell death. Cells were pre-treated with 0.8μM of PrP peptide for 72 hours followed by addition of H₂O₂ (500μM) for additional 12 hours (n=3). Ki67 staining was used to detect proliferating cells (red) (k and l) and cleaved caspase 3 staining (green) for apoptotic cells (k and m). **(n and o)** Reducing PrP^C by shRNA (l, n=3) and TCS (m, n=3) reduces cell-matrix adhesion. Data are presented as ±SEM (ns p>0.05, *p<0.05, **p<0.01, ***p<0.001). In i, j and k total cell number was monitored by DAPI staining (blue).

Figure 5.

Signalling pathways activated by PrP^C in schwannoma. **(a, c and e)** Reducing levels of PrP^C using *PRNP* shRNA significantly decreased levels of both total (a, dark grey bars, n=5) and pERK1/2 (a, light grey bar, n=5), pAKT^{S473} (c, light grey bars, n=5) but not total AKT (c, dark grey bars, n=5) and both total (e, dark grey bars, n=5) and pFAK^{Y397} (e, light grey bars, n=5). **(b, d and f)** Reducing levels of PrP^C using TCS significantly decreased levels of both total (b, dark grey bars, n=5) and pERK1/2 (b, light grey bar, n=5), pAKT^{S473} (d, light grey bars, n=5) but not total AKT (d, dark grey bars, n=5) and both total (f, dark grey bars, n=5) and pFAK^{Y397} (f, light grey bars, n=5). Data are presented as ±SEM (ns p>0.05, *p<0.05, **p<0.01, ***p<0.001). *PRNP*

shRNA from both Santa Cruz biotechnologies and GE healthcare were used and the results were merged (Supplementary figure 3ai and 3aii).

Figure 6.

Increasing PrP^C levels in normal Schwann cells (NF2+/+) leads them to obtain schwannoma-like properties. **(a-b)** Schwann cells treated with PrP (105 – 120) synthetic peptide for six days showed an increase in the number of Ki67-positive (a, n=3) and c-Jun-positive cells (b, n=3). **(c)** PrP synthetic peptide (105 – 120) altered cell morphology of Schwann cells over the course of six days and, even more so, after 2 weeks (c, phalloidin green, n=3). Cell area was measured using ImageJ software in n=52 cells (6 days) and in n=50 cells (2 weeks) (c right panel). **(d)** 6 days treatment with PrP (105 – 120) synthetic peptide the PrP in Schwann cells was still sensitive to proteinase K degradation (d, n=3). **(e-g)** overexpression of PrP^C with a clone of the *PRNP* gene significantly increases expression of Cyclin D1 (e and g, n=3) and c-Jun (f and g, n=3). Data are presented as \pm SEM (*p<0.05,**p<0.01, ***p<0.001).

Figure 7.

PrP^C interacts with and signals via the 37/67kDa non-integrin laminin receptor protein (LR). **(a and b)** PrP^C co-localises with LR in schwannoma throughout the cytosol and in the membrane of permeabilised cells (a, n=3) and in discrete membrane ruffles of non-permeabilised cells (b, n=3). **(c and d)** Co-immunoprecipitation (co-IP) of LR in schwannoma cell lysates pulls down PrP^C (c, n=5) and co-IP of PrP^C in schwannoma cell lysates pulls down LR (d, n=8). **(e-h)** Treatment of schwannoma cells with PrP (105 – 120) synthetic peptide increases levels of cyclin D1 (e light grey bars, n=5), pERK1/2 (f light grey bars, n=5), pAKT^{S473}

(g light grey bars, n=5) and pFAK^{Y397} (h light grey bars, n=5). LR knockdown using shRNA reduces the ability of PrP peptide to increase levels of cyclin D1 (e, dark grey bars, n=5), pERK1/2 (f dark grey bars, n=5), pAKT^{S473} (g dark grey bars, n=5) and pFAK^{Y397} (h dark grey bars, n=5). (i) Western blot pictures corresponding to (e-h) graphs. Data are presented as \pm SEM (ns $p>0.05$ *, $p<0.05$, ** $p<0.01$, *** $p<0.001$). Multi-track confocal microscopy z-stacks were used for co-localisation of immunofluorescence (a and b).

Supplementary Figure 1.

Western blot demonstrating **(a, left panel)** Merlin/NF2 status in human primary schwannoma cells (n=12 different patients) and (a, right panel) PrP expression and Merlin/NF2 status in human schwannoma tissues (n=7). **(b)** S100 staining on Schwann cell cultures. In (a, left) Merlin reintroduction was performed using recombinant adenovirus AdMerlin/NF2. GAPDH was used as a loading control.

Supplementary Figure 2.

Inhibition of NF κ B (green) translocation into the nucleus by NF κ B inhibitor SN50 (permeable inhibitory peptide). Schwannoma primary cells were treated with 8 μ g/ml SN50 for 72 hours and NF κ B localisation monitored by immunocytochemistry. DAPI is a nuclear marker (Blue).

Supplementary Figure 3.

Reduction of PrP^C using *PRNP* shRNA and anti-prion agent TCS.. **(a)** Treatment of schwannoma cells with a pool of five different *PRNP* shRNA hairpins (Santa Cruz) consistently reduced PrP^C expression (ai) as did homemade TRC lentivirus *PRNP*_88 (GE Dharmacon, aii). *PRNP* shRNA from both companies were equally effective in the decreasing of Cyclin D1 and pERK1/2 expression (ai, n=10 and aii, n=6; bottom panels). **(b)** Upon treatment with TCS at 20 μ M there was a tendency for PrP^C levels to be reduced although this was not significant, at 100 μ M and 500 μ M PrP^C expression in schwannoma was significantly reduced, n=10. Data are presented as \pm SEM (ns p>0.05, * p<0.05, **p<0.01, ***p<0.001).

Supplementary Figure 4.

Reduction of PrP^C decreases total cell number and the percentage of alive cells. **(a-d)** Upon reduction of PrP^C in schwannoma cells using both *PRNP* shRNA (a, n=6) and almost all concentrations of anti-prion agent TCS.(b, n=5), the total cell number, judged using DAPI, was reduced. Both *PRNP* shRNA (c, n=6) and high levels of anti-prion agent TCS (d, n=4) reduced the number of alive schwannoma cells. (e, n=3) PrP synthetic peptide (KTNMKH MAGAAAAGAC corresponding to amino acid residues 105 - 120 of the human prion protein, N-terminal) rescues schwannoma cells from H₂O₂-mediated cell death. Cells were pre-treated with 0.8μM of PrP peptide for 72 hours followed by addition of H₂O₂ (500μM) for additional 12 hours (n=3, MTS test). Number of alive cells was calculated by subtracting the number of condensed or fragmented nuclei from the total cell number. Data are presented as ± SEM (p>0.05, *p<0.05, **p<0.01, ***p<0.001).

Supplementary Figure 5.

Structure of the pLenti6.2/V5-DEST-PRNP overexpressing vector used to create *PRNP* overexpressing lentiviral particles. *PRNP* overexpressing clone was made using DNA corresponding to the coding region of the *PRNP* gene which was PCR cloned and inserted into pENTR11 entry vector before being gateway cloned into pLenti6.2/V5-DEST destination vector just after the CMV promoter region. Lentiviral particles containing the pLenti6.2/V5-DEST-PRNP vector were manufactured in HEK293FT cells before being collected and purified from the cell culture medium. Image courtesy of SnapGene®.

Supplementary Figure 6.

LR/37/67kDa (LR) expression. (a) LR is expressed both in Schwann cells (NF2+/+) and schwannoma cells (NF2-/-), there is no difference in LR expression between the two cell types, n=4. (b) Treatment of schwannoma cells with PrP (105-120) synthetic peptide but not a scramble mock peptide increases pAKT, showing specificity for the PrP (105-120) synthetic peptide, n=4. Data are presented as \pm SEM ($p>0.05$, $*p<0.05$, $**p<0.01$, $***p<0.001$).

Supplementary Figure 7.

The overexpression of PrP^C significantly increases levels of both Cyclin D1 and c-Jun in Schwann cells compared to the GFP-containing control. DNA from *PRNP* coding region (NCBI Reference Sequence: NG_009087.1) from O/E2B transformation starter colonies was used.